Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lytera 2.0 vs Hydroquinone in Melasma
NCT02977507Completed
- Sponsor
- Allergan
- Start
- Dec 2016
- Primary completion
- Oct 2017
- Countries
- 1
01
Overview
Randomised, double-blind trial in melasma (2 arms), sponsored by Allergan. Primary endpoints: Melasma Severity Rating Scale Score at 12 weeks, Overall Hyperpigmentation Scale Score at 12 weeks and 1 more. Started Dec 2016; status: completed.
02
Conditions
melasma
Beyond the preview
Go deeper on NCT02977507.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02977507.